Regeneron's Eylea hits double-digit growth for 2018 by Carly Helfand Wednesday, January 9, 2019 Investors had been worried that growth for Regeneron’s Eylea was slowing down, but Monday the company batted away those fears.
Alexion pivots to less-rare diseases—and a new pricing strategy by Carly Helfand Wednesday, January 9, 2019 Alexion aims to transform from an ultrarare-disease company to a rare-disease company—and to make that happen, its pricing has to change.
With Tesaro in the bag, Glaxo CEO's pumped about pipeline by Eric Sagonowsky Wednesday, January 9, 2019 CEO Emma Walmsley just put cancer back on the front burner, but with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says.
Lilly's Emgality launch paving the way for a pain franchise: exec by Eric Sagonowsky Wednesday, January 9, 2019 Despite its CGRP drug Emgality's third-to-market status, Lilly has big plans for a growing stable of migraine and pain drugs, an exec said.
JPM need-to-know, Part 2: GSK, Amgen, Lilly, Mylan and more by Tracy Staton Tuesday, January 8, 2019 What's on Tuesday's talking points memo at JPM? Drug launches, hoped-for FDA nods, deals, rivalries, FDA tea leaves—and one unexpected tax bill.
Merck's long M&A dry spell isn't for lack of trying: CEO by Carly Helfand Tuesday, January 8, 2019 There’s a reason Merck hasn’t made a big acquisition lately. And it’s not because it doesn’t want to.
Sanofi's learned Dengvaxia lessons, vaccines chief says by Eric Sagonowsky Tuesday, January 8, 2019 To make sense of Sanofi's Dengvaxia experiences, look no further than the old adage: Learn from your mistakes.
Novartis CEO eyes full 'game board' of cell, gene therapies by Eric Sagonowsky Monday, January 7, 2019 The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
JPM 2019, Day 1: Merck, J&J, Gilead, Pfizer and more by Tracy Staton Monday, January 7, 2019 Pharma came storming out of the gate at this year's J.P. Morgan meeting in a Monday full of deal talk, CEO ambitions and analyst prognostications.
JPM: BMS, Celgene CEOs trot out detailed case for $74B deal by Eric Sagonowsky Monday, January 7, 2019 CEOs for BMS and Celgene took to the J.P. Morgan Healthcare Conference to explain the rationale for their $74 billion megadeal.